Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

With extended treatment, mild to moderate increases in serum creatinine were observed uncommonly in patients with chronic hepatitis B and compensated liver disease treated with Hepsera for a median of 49 weeks up to a maximum of 240 weeks. Changes in serum creatinine were observed very commonly in patients pre- and post-transplantation with lamivudine-resistant liver disease and multiple risk factors for changes in renal function who were treated with Hepsera for up to 129 weeks, with a median time on treatment of 19 and 56 weeks, respectively. Clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of treatment with antiviral therapies for hepatitis B, including Hepsera. Special warnings and precautions for use are included in the package insert regarding monitoring of renal function, post-treatment exacerbations of hepatitis, and the occurrence of lactic acidosis and severe hepatomegaly with steatosis. Dosing instructions for patients with underlying renal impairment and for patients co-infected with HIV are also provided in the package insert, which is available for download online at www.hepsera.com.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including risks related to Gilead's ability to successfully commercialize tenofovir DF for chronic hepatitis B. For example, safety and efficacy data from additional clinical studies ma
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:9/29/2014)... PARIS , Sept. 30, 2014 ... and NYSE: SNY) today announced that a Phase 2a ... IL-4 and IL-13 signaling, met all primary and secondary ... polyps (CSwNP) who did not respond to intranasal corticosteroids. ... dupilumab for use in the treatment of another allergic ...
(Date:9/29/2014)... PHILADELPHIA , Sept. 29, 2014  Repeated exposure ... life is associated with early childhood obesity, say researchers ... in a retrospective study based on data from ... The researchers found that children with ... infancy were particularly more likely to be at risk ...
(Date:9/29/2014)... DIEGO , 29 septembre 2014 ... (TSE : 4568) et Ambit Biosciences (NASDAQ : AMBI), ont ... fusion définitif en vertu duquel Daiichi Sankyo fera ... circulation d,Ambit Biosciences à 15 dollars par action ... d,achat qui sera suivie d,une fusion avec une ...
Breaking Medicine Technology:Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 2Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 3Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 4Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 6Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 7Antibiotic Use by Age 2 Associated with Obesity Risk 2Antibiotic Use by Age 2 Associated with Obesity Risk 3Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
... AUSTIN, Texas, May 24, 2011 A paper published ... demonstrated that adding OVA1 to a physician,s preoperative ... ovarian cancers than a physician,s preoperative assessment alone. The ... the journal, which is the official publication of the ...
... Holdings, Inc. (OTCQB: ABHI), a leader in the development of ... has signed a new line of credit with East West ... to expire July 2011. The new line of credit expands ... the previous revolving line and extends the line by one ...
Cached Medicine Technology:OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 2OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 3OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 4AmbiCom Renews and Expands Line of Credit With East West Bank 2AmbiCom Renews and Expands Line of Credit With East West Bank 3
(Date:9/30/2014)... 30, 2014 Influenza is a significant ... can improve the efficacy of therapy, minimize overuse of ... disease in healthcare settings. Diagnostic tests available today vary ... The decision your laboratory makes in selecting the correct ... providers, is key to effective use of influenza diagnostics. ...
(Date:9/30/2014)... 3M has added four new thin VHB ... 3M 5906 , 3M 5907 , 3M ... which help create the strongest bond possible to a wide ... bonding to difficult surfaces such as paints, low surface energy ... and 5905 are designed specifically for electronic device engineers and ...
(Date:9/30/2014)... Seniors Guide will take part in running ... in Raleigh, to support Alzheimer’s North Carolina (AlzNC) in ... , Associate Publisher of Seniors Guide Magazine, Shannon Tippette, ... for the Raleigh-Durham-Chapel Hill areas of North Carolina for ... helping their team, “Eye of the Tiger”, reach their ...
(Date:9/30/2014)... 30, 2014 American Medical ID and ... agreement to raise awareness about Alzheimer’s disease and related ... people with these brain disorders. , American Medical ID ... AFA to the foundation to support its efforts to ... The ID bracelets and necklaces can be purchased via ...
(Date:9/30/2014)... Charlestown, RI (PRWEB) September 30, 2014 Dogs ... owner. Oftentimes, this involves spending time in the car travelling ... their canines have free run of the vehicle; however, this ... the owner as well. Royal Flush Havanese shares ... should always be routine practice. , There are many ways ...
Breaking Medicine News(10 mins):Health News:Alere Webinar Spotlights Optimal Flu Diagnostics to Keep Your Lab Ahead of the Curve 2Health News:Alere Webinar Spotlights Optimal Flu Diagnostics to Keep Your Lab Ahead of the Curve 3Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3Health News:Seniors Guide To Run in 203 Mile Alzheimer’s Awareness Relay in Raleigh, North Carolina 2Health News:Seniors Guide To Run in 203 Mile Alzheimer’s Awareness Relay in Raleigh, North Carolina 3Health News:American Medical ID and Alzheimer’s Foundation of America Team up to Increase Awareness about Alzheimer’s Disease and Related Dementias 2Health News:American Medical ID and Alzheimer’s Foundation of America Team up to Increase Awareness about Alzheimer’s Disease and Related Dementias 3Health News:Royal Flush Havanese Offers Tops On the Importance of Restraining Dogs In Cars 2Health News:Royal Flush Havanese Offers Tops On the Importance of Restraining Dogs In Cars 3
... so does survival, study finds , MONDAY, Feb. 8 (HealthDay ... with increased risk of death, researchers say. , In a ... again at age 89 in a group of 555 participants ... at 85 and 89 years, and a greater decline in ...
... ... Strash, FACHE, Chief Executive Officer with Oro Valley Hospital, on critical issues facing healthcare ... ... timely communication among different segments of the medical community, Jackson & Coker ( www.jacksoncoker.com ...
... , CINCINNATI , Feb. 8 Three ... "about right," according to a study of more than 65,000 ... of obesity over the past several years, the number of ... 1999 and 2007," says Nicholas M. Edwards , MD, ...
... triggering bone formation , MONDAY, Feb. 8 (HealthDay News) -- ... osteoporosis in lab mice and rats, a new study has ... gut hinders bone formation. Most current drugs for osteoporosis only ... "New therapies that inhibit the production of serotonin in the ...
... BETHESDA, Md. , Feb. 8 /PRNewswire-Asia/ ... Western healthcare,products and services in the People,s Republic of China , today ... , , Financial Highlights:, -- Revenue in ... over year to $46.5 million;, -- Net ...
... ... McDonald, have formed One2One Partners. The firm creates customized programs that strengthen the relationship ... an engaged workforce and minimize the threat of third-party intervention, regardless of potential legislation ... ...
Cached Medicine News:Health News:Handgrip Strength Helps Predict Death Risk in Elderly 2Health News:Jackson & Coker Industry Report Spotlights Healthcare Executive Interview, 2Health News:Jackson & Coker Industry Report Spotlights Healthcare Executive Interview, 3Health News:Jackson & Coker Industry Report Spotlights Healthcare Executive Interview, 4Health News:Jackson & Coker Industry Report Spotlights Healthcare Executive Interview, 5Health News:Jackson & Coker Industry Report Spotlights Healthcare Executive Interview, 6Health News:New Study Shows Nearly One Third of Overweight Adolescents See Themselves as Underweight or 'About Right' 2Health News:New Study Shows Nearly One Third of Overweight Adolescents See Themselves as Underweight or 'About Right' 3Health News:Drug Cures Osteoporosis in Mice 2Health News:Chindex International, Inc. Reports Third Quarter Fiscal Year 2010 Financial Results 2Health News:Chindex International, Inc. Reports Third Quarter Fiscal Year 2010 Financial Results 3Health News:Chindex International, Inc. Reports Third Quarter Fiscal Year 2010 Financial Results 4Health News:Chindex International, Inc. Reports Third Quarter Fiscal Year 2010 Financial Results 5Health News:Chindex International, Inc. Reports Third Quarter Fiscal Year 2010 Financial Results 6Health News:Chindex International, Inc. Reports Third Quarter Fiscal Year 2010 Financial Results 7Health News:Chindex International, Inc. Reports Third Quarter Fiscal Year 2010 Financial Results 8Health News:Chindex International, Inc. Reports Third Quarter Fiscal Year 2010 Financial Results 9Health News:Chindex International, Inc. Reports Third Quarter Fiscal Year 2010 Financial Results 10Health News:Chindex International, Inc. Reports Third Quarter Fiscal Year 2010 Financial Results 11Health News:Chindex International, Inc. Reports Third Quarter Fiscal Year 2010 Financial Results 12Health News:Chindex International, Inc. Reports Third Quarter Fiscal Year 2010 Financial Results 13Health News:Labor and Employee Relations Experts Form New Consulting Firm 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: